Small Intestinal Carcinoma

P2, N=28, Recruiting, Instituto do Cancer do Estado de São Paulo | Active, not recruiting --> Recruiting

This case indicates that CE can provide clinically useful information for the evaluation of small bowel submucosal lesions beyond the reach of conventional endoscopy. IMT should be considered in the differential diagnosis of erythematous small bowel tumors in young patients.

Malignant lymphoma should be considered in the differential diagnosis of acute obstructive symptoms, even when imaging findings suggest carcinoma. Prompt surgical intervention can facilitate definitive diagnosis and timely referral for systemic therapy in selected cases.

In this study, we extend previous work on binary outcomes to the application of Bayesian hierarchical models (BHMs) for extrapolation of overall survival from pembrolizumab-treated patients with microsatellite instability-high/deficient mismatch repair solid tumors.MethodsWe considered BHMs based on 1- or 2-parameter distributions for extrapolation of survival outcomes...The results provide extrapolated curves for OS that vary by tumor site, thus capturing and quantifying the inherent heterogeneity within the patient population. BHMs offer advantages in terms of reduced uncertainty around parameters that are often key drivers in cost-effectiveness analyses, such as estimated OS, through the borrowing of information between tumor sites.HighlightsBayesian hierarchical models (BHMs) reduced uncertainty in extrapolation of time-to-event outcomes for histology-independent treatments compared with nonhierarchical models fit to each tumor site.Reduced uncertainty around the mean survival time is a key factor of cost-effectiveness analyses of histology-independent treatments.BHMs provide a suitable framework for extrapolating histology-independent survival outcomes, effectively integrating prior knowledge and explicitly capturing heterogeneity between different tumor sites.

P=N/A, N=48, Completed, Theodor Bilharz Research Institute | Phase classification: P4 --> P=N/A

In contrast, one of the two cases with metachronous peritoneal metastases developed an additional KRAS mutation compared to the paired primary, shifted from moderately to poorly differentiated morphology, and exhibited mismatch-repair deficiency by immunohistochemistry, while remaining microsatellite stable by NGS. These findings suggest interlesional molecular heterogeneity in SBA and emphasize the need for re-biopsies in precision oncology for metachronous metastases.

Our work presents the largest UK cohort of DA with long-term follow-up making it an excellent resource for future biomarker studies. Validation studies in prospective clinical studies are required for clinical application.

P=N/A, N=420, Recruiting, Alliance for Clinical Trials in Oncology | Not yet recruiting --> Recruiting

Taxane-based therapy demonstrated activity in metastatic SBA, with 24% response and 3.1-month mTTP. TP53 mutation may be a negative predictive marker for taxane efficacy. These findings support prospective investigation in metastatic SBA.

These findings suggest that nonampullary duodenal neoplasms of gastric phenotype can be reclassified as "gastric-type adenomas" based on excellent prognosis and common genetic alterations, albeit a wide spectrum of morphology and gastric phenotypic expression. MDM2 amplification may contribute to histologic progression.

P2, N=36, Completed, Crinetics Pharmaceuticals Inc. | Active, not recruiting --> Completed

P=N/A, N=400, Recruiting, Assistance Publique - Hôpitaux de Paris